Despite the tremendous benefit of this treatment, the prospect of indefinitely adhering to the monthly treatment schedules of MARINA and ANCHOR has raised ocular and systemic safety concerns as well as convenience and cost issues for patient and physician alike. The identification of alternative dosing strategies capable of reducing the number of required anti-VEGF injections while still achieving favourable visual acuity outcomes has since been a subject of great interest. The current norm in clinical practice with Ranibizumab is to implement an 'initiation phase' followed by an individualized 'maintenance phase' that is modeled after one of two basic approaches: 'treat-and-observe' or 'treat-and-extend'. Both regimens are currently considered within the standard of clinical practice. 'Treat -and-observe' entails treatment and follow-up until the macula is free of exudation, with treatment thereafter only in the presence of recurrent exudation.7 Alternatively, in a treat-and-extend dosing strategy, intervals between treatments are extended as long as the macula remains dry.8 In the 2009 ASRS survey, 56% of physicians reported employing treat-and-observe and 44% reported employing treat-and-extend for their patients with neovascular AMD.9 In a study by Oubraham et al10 it was found that a treat-and-extend dosing regimen may yield greater gains in vision than treat-and-observe, albeit with a greater number of required injections.